Alnylam Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Alnylam Pharmaceuticals announced robust Q2 2026 results, driven by significant growth in AMVUTTRA sales and increased royalty revenue.
NASDAQ
Alnylam Pharmaceuticals announced a significant increase in total revenues, driven by strong product sales, particularly AMVUTTRA, and improved operational income.
NASDAQ
Alnylam Pharmaceuticals reported a significant increase in total revenues and net income for the third quarter and first nine months of 2025, driven by robust AMVUTTRA sales and a major milestone payment from Roche for zilebesiran.
NASDAQ
10-Q: Alnylam Reports Strong Product Revenue Growth Amidst Rising Losses and Patent Litigation Setbacks
Alnylam Pharmaceuticals announced significant increases in product revenue, driven by AMVUTTRA's expanded indications, but reported a widening net loss and faced adverse rulings in key patent infringement lawsuits.
NASDAQ
Alnylam Pharmaceuticals reports increased net product revenues and collaboration revenues in Q1 2025, driven by AMVUTTRA and strategic partnerships.
NASDAQ
10-Q: Alnylam Pharmaceuticals Reports Third Quarter 2024 Results, Highlights Progress in Key Programs
Alnylam Pharmaceuticals reports a net loss for the third quarter of 2024, despite a 34% increase in net product revenues, driven by growth in AMVUTTRA sales.
NASDAQ
Alnylam Pharmaceuticals' Q2 2024 results show significant revenue growth driven by product sales and collaborations, alongside ongoing clinical development advancements.
NASDAQ
Alnylam Pharmaceuticals reports a strong first quarter of 2024, with significant revenue growth driven by its key products and collaborations.